A historic moment…the first clinical trial to “reverse aging” begins next month

Professor and Professor of the Department of Genetics at the Blavatnik Institute, David Sinclair, announced that next month will witness the start of the first clinical trial on humans to test the possibility of reversing the aging process or slowing down aging and treating diseases associated with it, in a move he described as “a historic moment in human medicine.”

Sinclair said, during the World Government Summit, that we need to address all diseases at once, and this means aging, as aging is the cause of these diseases.

He stressed that this technology can be extended to give people longer, healthier, and more productive lives, which redefines aging and transforms it from a stage of deterioration to a period in which vitality and activity can be maintained until the ages of eighty and ninety.

He pointed out that the use of the three Yamanaka genes allows for the rejuvenation of cells by up to 75% within 6 weeks, without risking the creation of cancer cells. Previous experiments on animals have shown the ability to regrow tissue and repair optic nerves, which has cured cases of blindness in mice, as well as treated brain, liver and kidney diseases.

The Yamanaka genes are four transcription factors (Oct4, Sox2, Klf4, c-Myc) discovered by scientist Shinya Yamanaka in 2006, and are used to reprogram differentiated adult cells into a state similar to embryonic stem cells (induced pluripotent stem cells (iPSCs). This discovery enables tissue regeneration, reversal of aging, and treatment of diseases.